October 8, 2018

For today's bulletin, we take a look at our latest BUY upgrades. We also provide a link to download a FREE STOCK REPORT on Eli LIlly $LLY, one of our top upgrades for the day.

VALUATION WATCH: Overvalued stocks now make up 48.92% of our stocks assigned a valuation and 19.72% of those equities are calculated to be overvalued by 20% or more. Twelve sectors are calculated to be overvalued.

If you cannot display this bulletin properly, GO HERE

To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE

--UPGRADES

Top BUY-Rated Upgrades from ValuEngine

For today's edition of our upgrade list, we used our website's advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. There were no STRONG BUY upgrades today. All of the stocks below are rated BUY. ALso, we did not have five upgrades with full data, so Anixa Biosceince was provided to fill out the list.

Want to learn more about ValuEngine? Our methods? Our history?
Check out our video presentation HERE

Today, we take a look at Eli Lilly and Company (LLY). Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

ValuEngine updated its recommendation from HOLD to BUY for LILLY ELI & CO on 2018-10-05. Based on the information we have gathered and our resulting research, we feel that LILLY ELI & CO has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Company Size and Sharpe Ratio.

You can download a free copy of detailed report on Eli Lilly and Company (LLY) from the link below.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	115.64	0.54%
3-Month	115.67	0.57%
6-Month	118.32	2.87%
1-Year	122.41	6.43%
2-Year	121.70	5.81%
3-Year	124.47	8.21%

Valuation & Rankings
Valuation	10.39% overvalued	Valuation Rank(?)	33
1-M Forecast Return	0.54%	1-M Forecast Return Rank	86
12-M Return	31.23%	Momentum Rank(?)	86
Sharpe Ratio	0.94	Sharpe Ratio Rank(?)	91
5-Y Avg Annual Return	15.14%	5-Y Avg Annual Rtn Rank	85
Volatility	16.17%	Volatility Rank(?)	75
Expected EPS Growth	16.10%	EPS Growth Rank(?)	49
Market Cap (billions)	128.07	Size Rank	100
Trailing P/E Ratio	21.54	Trailing P/E Rank(?)	55
Forward P/E Ratio	18.55	Forward P/E Ratio Rank	34
PEG Ratio	1.34	PEG Ratio Rank	31
Price/Sales	5.36	Price/Sales Rank(?)	20
Market/Book	36.43	Market/Book Rank(?)	5
Beta	0.28	Beta Rank	68
Alpha	0.19	Alpha Rank	85

DOWNLOAD A FREE SAMPLE OF OUR ELI LILLY (LLY) REPORT BY CLICKING HERE

Steve Hach
Senior Editor
ValuEngine.Com